The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia
Abstract
We used flow cytometry to quantify minimal residual disease (MRD) in 56 patients with acute myeloid leukemia (AML) expressing a leukemia-associated phenotype. Thirty-four patients aged 18 to 60 years were entered into the AML-10 protocol (induction, consolidation, and autologous stem-cell transplantation [ASCT]), whereas 22 patients older than 60 years received the AML-13 protocol (induction, consolidation, and consolidation II). After induction, the level of MRD that was best associated with treatment outcome was 4.5 × 10−4 residual leukemic cells. However, the outcome in patients with at least 4.5 × 10−4 cells (n = 26) was not significantly different from that in patients with fewer leukemic cells (n = 30); there were 15 (58%) relapses in the first group and 12 (40%) relapses in the second. After consolidation, the most predictive MRD cutoff value was 3.5 × 10−4cells: 22 patients had an MRD level of 3.5 × 10−4 cells or higher and 17 (77%) of these patients had relapse, compared with 5 of 29 patients (17%) with lower MRD levels (P < .001). An MRD level of 3.5 × 10−4 cells or higher after consolidation was significantly correlated with poor or intermediate-risk cytogenetic findings, a multidrug resistance 1 (MDR1) phenotype, short duration of overall survival, and short duration of relapse-free survival (P = .014, .031, .00022, and .00014, respectively). In multivariate analysis, this MRD status was significantly associated with a high frequency of relapse (P < .001) and a short duration of overall (P = .025) and relapse-free survival (P = .007). ASCT did not alter the prognostic effect of high MRD levels after consolidation: the relapse rate after transplantation was 70%. Thus, we found that an MRD level of 3.5 × 10−4 cells or higher at the end of consolidation strongly predicts relapse and is significantly associated with an MDR1 phenotype and intermediate or unfavorable cytogenetic findings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
International System for Human Cytogenetic Nomenclature
National Cancer Institute (2020) · Definitions · doi:10.32388/78qroa · Cited by 6,840
ISCN 1995 An international system for human cytogenetic nomenclature
Mitelman, F. (1995) · Cited by 1,930
Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia
Mayer, R. J., Davis, R. B., Schiffer, C. A., Berg, D. T., Powell, B. L., Schulman, P., Omura, G. A., Moore, J. O., McIntyre, O. R., & Frei, E. (1994) · New England Journal of Medicine · doi:10.1056/nejm199410063311402 · Cited by 1,427
Aversa, F., Tabilio, A., Velardi, A., Cunningham, I., Terenzi, A., Falzetti, F., Ruggeri, L., Barbabietola, G., Aristei, C., Latini, P., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199810223391702 · Cited by 1,168
Zittoun, R. A., Mandelli, F., Willemze, R., de Witte, T., Labar, B., Resegotti, L., Leoni, F., Damasio, E., Visani, G., Papa, G., et al. (1995) · New England Journal of Medicine · doi:10.1056/nejm199501263320403 · Cited by 849
Cheson, B. D., Cassileth, P. A., Head, D. R., Schiffer, C. A., Bennett, J. M., Bloomfield, C. D., Brunning, R., Gale, R. P., Grever, M. R., & Keating, M. J. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.5.813 · Cited by 770
Burnett, A. K., Goldstone, A. H., Stevens, R. M., Hann, I. M., Rees, J. K., Gray, R. G., & Wheatley, K. (1998) · The Lancet · doi:10.1016/s0140-6736(97)09214-3 · Cited by 563
A randomized study of high-dose cytarabine in induction in acute myeloid leukemia [see comments]
Bishop, J., Matthews, J., Young, G., Szer, J., Gillett, A., Joshua, D., Bradstock, K., Enno, A., Wolf, M., & Fox, R. (1996) · Blood · doi:10.1182/blood.v87.5.1710.1710 · Cited by 458
Cited by
Schuurhuis, G. J., Heuser, M., Freeman, S., Béné, M.-C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T., Hills, R. K., Hourigan, C. S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-801498 · Cited by 1,041
Self-citationLim, Z.-F., & Ma, P. C. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0818-2 · Cited by 630
Terwijn, M., van Putten, W. L. J., Kelder, A., van der Velden, V. H. J., Brooimans, R. A., Pabst, T., Maertens, J., Boeckx, N., de Greef, G. E., Valk, P. J. M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9628 · Cited by 442
van Rhenen, A., van Dongen, G. A. M. S., Kelder, A., Rombouts, E. J., Feller, N., Moshaver, B., Walsum, M. S.-V., Zweegman, S., Ossenkoppele, G. J., & Jan Schuurhuis, G. (2007) · Blood · doi:10.1182/blood-2007-03-083048 · Cited by 439
Walter, R. B., Gooley, T. A., Wood, B. L., Milano, F., Fang, M., Sorror, M. L., Estey, E. H., Salter, A. I., Lansverk, E., Chien, J. W., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.8121 · Cited by 405
Metadata
- Authors
- Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., Battaglia, A., Catalano, G., Del Moro, B., Cudillo, L., Postorino, M., Masi, M., & Amadori, S.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2000-12-01
- Volume
- 96
- Issue
- 12
- Pages
- 3948-3952
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2104411649
- Cited by
- 275
- References
- 17
- FWCI
- 8.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. https://app.cochat.ai/papers/10.1182/blood.v96.12.3948
- The paper
- Venditti, A., Buccisano, F., Del Poeta, G., Maurillo, L., Tamburini, A., Cox, C., Battaglia, A., Catalano, G., Del Moro, B., Cudillo, L., Postorino, M., Masi, M., & Amadori, S. (2000). Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. https://doi.org/10.1182/blood.v96.12.3948
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.